Antibiotic resistance genes in general
IP aspects
Monsanto Company holds patent rights on the use of any antibiotic resistance gene as a selectable marker for plant transformation. Importantly, these proprietary rights apply only in the United States and are covered by three granted patents:
These three United States patents are related to three other United States patents and one European patent. However, the other patents are directed to the more specific subject matter of chimeric genes for plant transformation containing the 35S Cauliflower Mosaic Virus (CaMV) promoter or the promoter of the ribulose−1,5−bis−phosphate carboxylase small subunit (rbcS) gene in combination with the neomycin phosphotransferase (npt) gene as the antibiotic resistance gene.
These patents directed to promoters are analysed in the technology landscape Promoters.
Bibliographic data
|
Title |
Chimeric genes suitable for expression in plant cells |
||
|---|---|---|---|
|
Application No and Filing Date |
No. 07/333,802 |
No. 08/435,951 |
No. 09/228,638 |
|
Issue Date |
July 23, 1991* |
January 16, 2001** |
July 3, 2001† |
|
Remarks |
This patent is related to the US patent 6174724 through at least five different applications. |
These two patents are only related through the earliest priority document (the first patent application ever filed on the inventions) which corresponds to the United States application 458414 filed on January 17, 1983. |
|
|
* Patent term is 17 years from the date of issuance. |
|||
The information contained in this page was believed to be correct at the time it was collated. New patents and patent applications, altered status of patents, and case law may have resulted in changes in the landscape. CAMBIA makes no warranty that it is correct or up to date at this time and accepts no liability for any use that might be made of it. Corrections or updates to the information are welcome. Please send an email to info@bios.net.


